Loading Events
This event has passed.

We know that the recent NICE decisions about the drugs ibrutinib and zanubrutinib are a cause for worry for many in the WM community. Our CEO, Jane Nicholson, who has been working with NICE and the drug companies involved during the processes join us for a Q&A session about what the decisions mean for you, and what comes next.

Register now

Can’t make this session? We’ll be repeating the session on Thursday at 8pm. Register here.

Share This Story, Choose Your Platform!